Parvovirus formulation for treating tumors
US-10624935-B2 · Apr 21, 2020 · US
Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
US11027013B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11027013-B2 |
| Application number | US-201816148257-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 1, 2018 |
| Priority date | Apr 1, 2016 |
| Publication date | Jun 8, 2021 |
| Grant date | Jun 8, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical combination containing (a) parvovirus H-1 and (b) an anti-PD1 antibody or an anti-PD-L1 antibody. 2. The pharmaceutical combination of claim 1 , wherein the anti-PD 1-antibody is pembrolizumab or nivolumab. 3. The pharmaceutical combination of claim 1 , further comprising one or more additional therapeutic agents selected from chemotherapeutic agents, biotherapeutic agents, an immunogenic agents, immune stimulating cytokines and cells transfected with genes encoding immune stimulating cytokines. 4. A kit which comprises a first container, a second container and a package insert, wherein the first container comprises at least one dose of a pharmaceutical composition containing parvovirus H-1, the second container comprises at least one dose of a pharmaceutical composition comprising an anti-PD1 antibody or an anti-PD-L1 antibody, and the package insert comprises instructions for treating an individual having cancer using the pharmaceutical composition(s). 5. The kit of claim 4 , wherein the cancer is brain cancer, colon cancer, bladder cancer, liver cancer, breast cancer kidney cancer, head/neck squamous cell carcinoma, lung cancer, malignant melanoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer or stomach cancer. 6. The kit of claim 5 , wherein the brain cancer is glioblastoma multiforme.
Assignees
Inventors
Classifications
Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title
containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title
from primates, e.g. man · CPC title
against CD28 or CD152 · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11027013B2 cover?
- The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.
- Who is the assignee on this patent?
- Deutsches Krebsforsch, Univ Heidelberg Ruprecht Karls
- What technology area does this patent fall under?
- Primary CPC classification A61K39/3955. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).